Use of total parenteral nutrition in children with cancer: a review and some recommendations.

Abstract

Total parenteral nutrition (TPN) is now a standard component of supportive treatment in many pediatric oncology units for patients undergoing intensive therapy. TPN incurs many risks and significant costs, however, that may not always be balanced by major benefits. Infection rates are reported to be high in patients receiving TPN, and TPN use is associated with a range of metabolic problems. With standard TPN regimens, the catabolic state of many intensively treated patients may not be adequately reversed. Because TPN may enhance tumor cell growth, there is justifiable concern about giving TPN when a cancer patient is not also receiving cytotoxic therapy. Recommendations for TPN use in pediatric oncology patients include using TPN formulas containing glutamine to stimulate anabolism and timing TPN cycles to be given just before cytotoxic chemotherapy, when stimulation of tumor growth might actually improve the effectiveness of antimitotic chemotherapy.